186 related articles for article (PubMed ID: 32353006)
1. Generic escitalopram initiation and substitution among Medicare beneficiaries: A new user cohort study.
Li C; Chen L; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Wang Z; Qian J
PLoS One; 2020; 15(4):e0232226. PubMed ID: 32353006
[TBL] [Abstract][Full Text] [Related]
2. Patient factors associated with oral generic olanzapine initiation and substitution among Medicaid beneficiaries: a new user cohort study.
Mishuk AU; Chen L; Li C; Huo N; Hansen RA; Harris I; Kiptanui Z; Qian J
Curr Med Res Opin; 2021 Apr; 37(4):655-664. PubMed ID: 33507825
[TBL] [Abstract][Full Text] [Related]
3. Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study.
Huo N; Chen L; Ullah Mishuk A; Li C; Hansen RA; Harris I; Kiptanui Z; Wang Z; Dutcher SK; Qian J
Endocrine; 2020 May; 68(2):336-348. PubMed ID: 31993992
[TBL] [Abstract][Full Text] [Related]
4. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
Carroll NV
J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
[TBL] [Abstract][Full Text] [Related]
5. Oral generic tacrolimus initiation and substitution in the Medicaid population: a new user cohort study.
Chen L; Li C; Huo N; Mishuk AU; Hansen RA; Harris I; Kiptanui Z; Qian J
Curr Med Res Opin; 2020 Sep; 36(9):1533-1540. PubMed ID: 32644886
[TBL] [Abstract][Full Text] [Related]
6. Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
Wu EQ; Yu AP; Lauzon V; Ramakrishnan K; Marynchenko M; Ben-Hamadi R; Blum S; Erder MH
Ann Pharmacother; 2011 Apr; 45(4):441-51. PubMed ID: 21415162
[TBL] [Abstract][Full Text] [Related]
7. Low-Cost Generic Program Use by Medicare Beneficiaries: Implications for Medication Exposure Misclassification in Administrative Claims Data.
Pauly NJ; Talbert JC; Brown J
J Manag Care Spec Pharm; 2016 Jun; 22(6):741-51. PubMed ID: 27231801
[TBL] [Abstract][Full Text] [Related]
8. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
[TBL] [Abstract][Full Text] [Related]
9. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of generic versus brand-name antiepileptic medications.
Gagne JJ; Kesselheim AS; Choudhry NK; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Epilepsy Behav; 2015 Nov; 52(Pt A):14-8. PubMed ID: 26386779
[TBL] [Abstract][Full Text] [Related]
11. Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
Tungol A; Starner CI; Gunderson BW; Schafer JA; Qiu Y; Gleason PP
J Manag Care Pharm; 2012; 18(9):690-700. PubMed ID: 23206212
[TBL] [Abstract][Full Text] [Related]
12. Generic alendronate use among Medicare beneficiaries: are Part D data complete?
Yun H; Curtis JR; Saag K; Kilgore M; Muntner P; Smith W; Matthews R; Wright N; Morrisey MA; Delzell E
Pharmacoepidemiol Drug Saf; 2013 Jan; 22(1):55-63. PubMed ID: 23135758
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly JG; Fischer MA; Kesselheim AS; Gagne JJ
PLoS Med; 2019 Mar; 16(3):e1002763. PubMed ID: 30865626
[TBL] [Abstract][Full Text] [Related]
14. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
15. Changes in the Use of Brand Name and Generic Medications and Total Prescription Cost Among Medicare Beneficiaries With Epilepsy.
Terman SW; Lin CC; Kerr WT; DeLott LB; Callaghan BC; Burke JF
Neurology; 2022 Aug; 99(8):e751-e761. PubMed ID: 35705496
[TBL] [Abstract][Full Text] [Related]
16. Healthcare expenditure in severely depressed patients treated with escitalopram, generic SSRIs or venlafaxine in the UK.
Wade AG; Saragoussi D; Despiégel N; François C; Guelfucci F; Toumi M
Curr Med Res Opin; 2010 May; 26(5):1161-70. PubMed ID: 20297951
[TBL] [Abstract][Full Text] [Related]
17. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Desai RJ; Sarpatwari A; Dejene S; Khan NF; Lii J; Rogers JR; Dutcher SK; Raofi S; Bohn J; Connolly J; Fischer MA; Kesselheim AS; Gagne JJ
BMJ; 2018 Apr; 361():k1180. PubMed ID: 29615391
[TBL] [Abstract][Full Text] [Related]
18. Patterns and predictors of generic narrow therapeutic index drug use among older adults.
Gagne JJ; Polinski JM; Kesselheim AS; Choudhry NK; Hutchins D; Matlin OS; Tong A; Shrank WH
J Am Geriatr Soc; 2013 Sep; 61(9):1586-91. PubMed ID: 24001285
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Switch-to-Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real-World Retrospective Cohort Study.
Kalaria S; Spence O; Hong K; dosReis S; Gopalakrishnan M
Clin Pharmacol Ther; 2021 Aug; 110(2):443-451. PubMed ID: 33811324
[TBL] [Abstract][Full Text] [Related]
20. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study.
Gagne JJ; Choudhry NK; Kesselheim AS; Polinski JM; Hutchins D; Matlin OS; Brennan TA; Avorn J; Shrank WH
Ann Intern Med; 2014 Sep; 161(6):400-7. PubMed ID: 25222387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
